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Abstract 
Amyloids may be regarded as native nanomaterials that form in the presence of complex 
protein mixtures. By drawing an analogy with the physicochemical properties of 
nanoparticles in biological fluids, we hypothesized that amyloids should form a protein 
corona in vivo that would imbue the underlying amyloid with a modified biological identity. 
To explore this hypothesis we characterized the protein corona of human islet amyloid 
polypeptide (IAPP) fibrils in FBS using two complementary methodologies developed herein; 
quartz crystal microbalance and ‘centrifugal capture’, coupled with nano-liquid 
chromatography tandem mass spectroscopy.  Clear evidence for a significant protein corona 
was obtained.  No trends were identified for amyloid corona proteins based on their 
physicochemical properties, while strong binding with IAPP fibrils occurred for linear 
proteins or multi-domain proteins with structural plasticity. Proteomic analysis identified 
amyloid-enriched proteins that are known to play significant roles in mediating cellular 
machinery and processing, potentially leading to pathological outcomes and therapeutic 
targets.  
 
 
 
 
Keywords: amyloid, protein corona, liquid chromatography, mass spectrometry, 
amyloidogenesis  
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The dynamic and nonspecific adsorption of proteins on a nanoscale substrate renders a 
‘protein corona’, which consequently defines the biological identity of the nanostructure.1 
The physicochemical and biological properties of the protein corona have been extensively 
examined in the last decade,2 and characterizations of these aspects have become a necessity 
for establishing any engineered nanomaterial designed for biological applications.  
Native biomaterials resemble engineered nanoparticles in mechanical and physicochemical 
attributes, but acquire these traits through endogenous processes that include the formation of 
‘native’ protein coronae. The capacity for biomaterials to interact with surrounding biological 
media supports the hypothesis that, similar to nanomaterials, the surface properties and 
biological behavior of biomaterial-corona complexes diverges from that observed for isolated 
materials prepared in vitro.3,4 This is exemplified by extracellular matrix component 
fibronectin, which demonstrated the ability to foul upon mechanically-induced unwinding.5 
Viral particles also displayed the capacity to form protein coronae in biological fluids, and 
such coronae appeared to direct viral pathogenesis and catalyze amyloid aggregation.6 
Whereas protein absorption to synthetic nanomaterials can result in rapid clearance from the 
circulation,7  protein corona formation on native nanomaterials as they are produced and 
secreted into intra- or extracellular environment may play a role in their endogenous function, 
and in maintaining their biological stability. 
Amyloid fibrils represent a major class of native nanomaterial. They manifest as long, semi-
flexible, hydrophobic nanofibers formed through aggregation of amyloid proteins that are 
ubiquitously present in the body.8 While amyloids can be involved in functional processes, 
such as in melanin production,9 amyloidogenesis is a deleterious process implicated in 
metabolic and neurodegenerative pathologies that present a major burden on global health.8  
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Here, we consider human islet amyloid polypeptide (IAPP): a 37-residue amyloidogenic 
peptide that is co-secreted with insulin from pancreatic β-cells in vivo, and stabilized within 
intracellular β-cell granules prior to secretion by a combination of low pH, insulin and 
complexation with C-peptide and zinc ions at a specific ratio.10 IAPP plays a functional role 
in glycemic control,11 and a pathological role in the development and morbidity of type 2 
diabetes (T2D)12 through their amyloid aggregation within the extracellular space, a process 
toxic to the β-cells.13 Although IAPP amyloid deposition is largely associated with cell death 
and dysfunction in the pancreas,13 extra-pancreatic plaques and associated cytotoxicity have 
also been observed in the heart,14 kidney15 and brain.16,17 Given that plasma amylin 
concentration is either unchanged,18 or even decreased,19 in patients with T2D when 
compared to non-diabetics, it is likely that amyloid nucleation components from pancreatic 
deposits, including fibrils, are capable of translocating into the circulation where they 
subsequently develop into distal plaques that contribute to extra-pancreatic T2D pathologies. 
Given the long biological lifetime of amyloid deposits,20,21 particularly when compared to 
synthetic nanomaterials,22,23 the formation and implications therein of an ‘amyloid-protein 
corona’ may elicit extensive and wide-ranging effects on biological processes, thus belying a 
more complex role in amyloid-associated disease pathologies.  
IAPP amyloids are capable of associating with numerous proteins and co-factors in vivo, 
including serum amyloid P component,24 apolipoprotein E,25 and glycosaminoglycans 
(GAGs), in particular heparan sulfate proteoglycans.26 GAGs have demonstrated the capacity 
to enhance fibrillization of both functional27,28 and incompletely processed IAPP,31 and are 
subsequently implicated in IAPP-associated cytotoxicity.29,30 We have recently established 
the capacity for IAPP amyloids to form a protein corona in vitro to impact the amyloid 
morphology and cytotoxicity.32 As an extension, herein we present a comprehensive 
qualitative annotation of the complex protein corona formed on the major pathological 
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amyloid IAPP.  Fetal bovine serum (FBS) was utilized as a representative medium, 
mimicking the in vivo milieu and providing context for amyloid studies in vitro. Time point-
based analyses of corona deposition by transmission electron microscopy (TEM) and quartz 
crystal microbalance (QCM) revealed rapid formation of a viscoelastic, non-uniform protein 
corona on IAPP amyloids within seconds of exposure to FBS.33 Helium ion microscopy 
(HIM) imaging highlighted the capacity for the amyloid-protein corona to disrupt cell 
morphology within minutes of exposure. Modified QCM and ‘centrifugal capture’ (CC) 
techniques provided independent work flows for ‘one-pot’ amyloid-protein corona isolation, 
elution and tryptic digestion for subsequent analysis by nano-liquid chromatography tandem 
mass spectroscopy (nLC-MS/MS). Replicate QCM and CC experiments revealed that the 
IAPP amyloid corona is composed of multiple protein types with varied biological functions, 
including adhesion and signal transduction. This study provides insights into the influence of 
proteins on the properties of IAPP amyloids, including their toxicity. In addition, methods in 
this study offer a prototype pipeline applicable to other amyloid proteins, and thus have 
implications for the rational design of effective strategies against amyloid pathologies in vivo.  
 
Results and Discussion  
Amyloids rapidly formed a protein corona in complex solution. TEM imaging revealed serum 
proteins associating with mature IAPP amyloids within seconds of mixing (Fig. 1A). After 24 
h an amyloid-protein corona was established that visibly changed amyloid morphology (Fig. 
1A, upper panels). IAPP amyloids formed in water were long, semi-flexible nanofibers with a 
narrow width distribution, presenting an average diameter of 8.5 ± 1.9 nm (Fig. 1A, lower 
panel); in contrast, introduction of FBS immediately (T = 0 min) increased the average fibril 
width by 3 nm. By 24 h, the average recorded fibril width nearly doubled that of the control 
amyloids. This significant shift in fibril diameter upon formation of the IAPP amyloid-FBS 
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protein corona showed high concordance with an independently conducted assay (Fig. 1A, far 
right panels), wherein IAPP amyloids were incubated with human plasma proteins at an 
analogous mass ratio and measured after 24 h (average fibril diameter: 16 ± 5.53 nm).  
The rapid formation and large structural variance of the IAPP amyloid-protein corona 
observed with TEM was corroborated by QCM measurements (Fig. 1B). Gold-coated QCM 
sensors were functionalized with IAPP amyloids in a two-step process to ensure coverage of 
the full sensor surface: an initial incubation period under static conditions over 16 h, followed 
by a second passivation step under flow for 1 h (Fig. S1, Supporting Information). IAPP 
amyloid displayed cumulative deposition as per ‘classical’ behavior of pathological amyloids 
in vivo.34 Passivation of FBS onto the IAPP amyloid-functionalized QCM sensor 
demonstrated an exponential protein deposition onto amyloid within the first 15 min of 
exposure at a flow rate of 100 µL/min. Saturation under these conditions was observed to 
occur at circa 1 h. Surprisingly, these kinetics were very comparable to protein deposition 
onto the non-functionalized gold surface, to which proteins had a strong binding affinity due 
to the ubiquity of thiol-rich cysteine residues, suggesting amyloids may initiate similar 
protein interactions in vivo. Upon removal of transiently bound proteins through a wash step, 
protein deposition onto non-functionalized control sensors correlated to a dissipation shift of 
close to zero, indicating formation of a rigid, compressed protein layer, with little variation 
observed over individual runs. In contrast, the final mean dissipation shift when serum 
proteins bound to IAPP amyloids was 7.4×10-6 with extensive variations between 
independent runs, indicating that a viscoelastic, elongated surface coating of proteins was 
able to form on IAPP amyloid plaques and that this surface was non-uniform in character, 
thus concordant with TEM observations. Furthermore, after removal of unbound FBS, little 
change in the frequency shift was observed, providing strong evidence that protein 
association to amyloid was not transient, but most likely involved at minimum the formation 
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of a ‘hard’ corona within an hour of protein exposure. The facile association of proteins with 
the IAPP amyloid surface observed here can be attributed to the physicochemical properties 
of the amyloid exposed moieties. Namely, basic lysine (Lys1; pKa=10.54) and arginine 
(Arg11; pKa=12.48) are protonated at physiological conditions and can form H-bonds; 
concordantly, polar tryptophan (Thr4, Thr6 and Thr9) and aromatic phenylalanine (Phe15) 
are known to form hydrophobic and π-π stacking interactions.35,36 
IAPP amyloid with associated proteins affected pancreatic β-cell morphology. IAPP 
amyloids with no pre-exposure to protein solution (Fig. 1C, panel I), amyloids pre-incubated 
with FBS for 2 h at room temperature (II), and FBS in absence of amyloid (III) were 
incubated with insulin-producing pancreatic β-cell line βTC6 in suspension for 30 min. Cells 
were then fixed and imaged by helium ion microscopy (HIM). βTC6 cells exposed to IAPP 
amyloids, with or without preformed coronae, displayed a shift in morphology from the 
rounded, smoother cell surface – visualized for those where amyloid was absent (III) and for 
untreated controls (IV) – to a flattened morphology with a highly folded cell membrane 
(III&IV). Pathological amyloids have been shown to affect cell membrane fluidity, through 
means of intercalation and lipid-stripping;37-39 as such, these data suggest that rapid amyloid-
protein corona formation in cell culture media over the 30 min treatment period was no less 
protective against amyloid-membrane interactions than the introduction of amyloids with a 
preformed corona over 2 h. 
Amyloid-protein corona was effectively isolated using two independent methodologies. Two 
distinct methods were optimized to isolate a complex protein-protein corona for composition 
analysis by nLC-MS/MS. The sample preparation goal was to adopt orthogonal approaches 
for achieving ‘one-pot’ – and therefore streamlined – isolation, digestion and elution of 
corona proteins from captured amyloid. The first of these methods, CC, utilized high 
molecular weight cut-off (MWCO) spin columns (1 MDa) to separate amyloid and amyloid-
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protein complexes from free, unbound proteins via low-impact benchtop centrifugation, 
following in-solution formation of coronae over 2 h. CC demonstrated up to 90% amyloid 
retention and less than 10% nonspecific serum protein retention on the filter after four wash 
cycles (Fig. S2). In parallel, a second method incorporating quartz crystal microbalance 
(QCM) allowed the study of protein corona formation under flow; wherein IAPP amyloid 
captured on the sensor surface as large contiguous ‘plaques’ was able to collect serum 
proteins over time, thus providing further insights on amyloid-protein interactions combined 
with physical exposure conditions that more closely mimic those in vivo.40 For both CC and 
QCM, amyloid-protein corona isolation was followed by an in situ (on-filter for CC; on-
sensor for QCM) protein elution and ‘soft’ digestion protocol which maximized collection of 
corona proteins while minimizing the digestion of amyloid. This limited amyloid 
contamination for the subsequent nLC-MS/MS measurements, the results of which were 
submitted for protein database queries using the Andromeda search engine (MaxQuant)41,42 to 
determine which proteins could be identified in the amyloid-protein corona complex isolates. 
Together, CC and QCM provided different perspectives on the protein corona of a 
proteinaceous amyloid system – a complex analytical challenge – resulting in evidence that 
directly implicates these coronae in key protein pathways. The qualitative nature of shotgun 
nLC-MS/MS made this a post-hoc exploratory analysis of amyloid coronae components with 
the aim of generating testable hypotheses regarding the implications of coronal enrichment. 
Figure 2 highlights the workflow used to assess each experiment type: for CC these were 
amyloid only (A), FBS only (F) and amyloid-corona complexes (AF), while for QCM these 
were FBS only (EF) and amyloid-corona complexes (AE). In brief, further analysis included 
consideration of identification overlaps between experiments; namely, pooled searches for 
each experiment type to maximize IDs, and independent searches for technical replicates of 
experiments F and AF to establish the robustness of identification across replicates (see 
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Supporting Information). In addition, trends were sought in the relationships between Grand 
Average of Hydropathy (GRAVY), isoelectric point (pI) and molecular weight (MW), the 
proportion contribution of specific amino acid classes to corona protein sequences, as well as 
the existence of enriched gene ontologies (GO), pathways and protein domains in the protein 
networks (STRING analysis) formed by the individual proteins or peptides identified as being 
part of the amyloid protein corona and found lacking in the background controls, hereafter 
referred to as ‘unique’ proteins (see Supporting Information for details of processing and 
presentation).  
Isolation method impacts protein identification rates and similarity of composition. A 
primary reason for using both CC and QCM approaches was the potential for producing 
vastly different protein coronae: through corona formation in different environmental 
conditions. Given that little is known regarding the composition of amyloid coronae, the 
nLC-MS/MS identifications for these orthogonal approaches were contrasted in the context 
of both experimental design and the existing knowledgebase regarding synthetic nanomaterial 
coronae. 
The CC method – inspired by separation approaches applied to synthetic nanomaterials43 – 
was hypothesized to drive the formation of relatively ‘simple’ amyloid-protein complexes in-
solution, which were both formed and washed under relatively turbulent conditions (i.e. 
rinsing/centrifugation) leaving only the ‘hard’ corona intact.43 This was considered in concert 
with the concept of a relatively large MWCO filter being able to effectively retain fibril 
complexes,44 where the remainder of the proteins in-solution would bypass the filter. In sharp 
contrast, the gentle QCM micro-flow conditions – for amyloid deposition, FBS application 
and PBS rinsing – not only generated complex surface associated plaque structures, but 
created conditions more conducive to preserving a triad of binders: high-affinity ‘hard’ 
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corona proteins, any sterically captured proteins as well as secondary/tertiary protein-protein 
‘soft’ corona binders.40 
CC controls were considered first. A total of 50 proteins were identified in the amyloid fibrils 
only (A) sample, which may have been derived from column carryover or present as 
contaminants in solution. Not unexpectedly, using a Human *.fasta file, sample A was also 
found to also contain multiple Keratins (see Supporting Information). Overall, the CC (F/AF) 
and QCM (EF/AE) experiments resulted in 961 (Fig. 3A) and 526 (Fig. 3B) protein 
identifications, respectively. The overall difference can be attributed to either inter-
experimental variation, or to the greater number of F/AF nLC-MS/MS analyses: 13, as 
compared to 8 for EF/AE. The overlap between the F and AF conditions accounted for 45.6% 
of the total identifications made with the CC method, while only 17.5% were shared between 
the FBS only (EF, N = 134 total and 42 unique proteins) and FBS in the presence of amyloid 
plaques (AE, N = 484 total and 392 unique proteins). This difference was likely caused by a 
combination of non-specific protein binding to the MWCO filter – see the retention of protein 
mass in Fig. S2 – in addition to trapping of protein aggregates in the spin filter. Here, given 
the robust wash steps being used for the CC method, the unique identifications may represent 
the “hard” protein corona formed around the fibrils, whereas the overlap proteins are part of 
the aforementioned “non-specific” noise in the preparation. As such, the unique AF proteins 
were marked as potentially interesting, given their absence across the numerous F sample 
control measurements. However, it could not be ruled out that these proteins were present in 
the F samples, but below the concentration required for detection by the applied nLC-MS/MS 
method. Next-stage application of label free quantitation (LFQ) by nLC-MS/MS may 
highlight the contribution of the F/AF overlap proteins to the corona, as relative quantity can 
provide enrichment information. 
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The sizeable difference in overlap profiles for the QCM experiments (EF/AE), as compared 
to the CC methods (F/AF), indicated that QCM micro-flow conditions may prevent the 
buildup and capture of large non-specific protein aggregates, but also preserve a different 
kind of binding complex: one combining high-affinity corona binders, proteins that become 
sterically trapped in the plaque-protein complex, and finally any secondary and tertiary 
protein-protein interactions that comprise a ‘soft’ amyloid corona.45 An alternative hypothesis, 
given that coronae are implicated in conformational change46 is that the amyloids catalyze the 
formation of protein aggregates that subsequently form a cloud around the fibril. A natural 
extension of this is that the use of alternative wash fluids could remove the lower affinity 
binders to reveal the ‘hard’ corona. These are exciting possibilities, as they suggest the data 
herein may provide a glimpse of a hard and soft coronae dichotomy for amyloid fibrils.  
Sequence-dependent characteristics do not indicate significant trends in properties for 
amyloid-corona proteins. Two independent analytical approaches were used to qualitatively 
evaluate the unique protein populations for the CC (AF) and QCM (AE) prepared coronae. 
The first of these was to consider the physicochemical properties of the protein sequences 
identified. Figure 3C shows the GRAVY – pI relationships for unique AF proteins (yellow) 
overlaid onto unique F proteins (blue) and the Bos taurus proteome, with a zoom view in Fig. 
3D. Although proteins with outlier values were observed for both GRAVY (PTMA, APP) and 
pI (PTMA, HIST1H2B1, H2AFV, Fig. 3C), no significant general trend was observed. The 
identification of Amyloid beta A4 protein (APP; see Fig. S4) here is interesting given the 
potential for assembly of heterogeneous amyloid structures comprised of both IAPP and 
APP.47 
There was also no clearly discernible pattern for an overlay of unique AE (yellow) and 
unique EF (blue) proteins onto the Bos taurus proteome (Fig. 3E, zoom in 3F). The AF / F 
and AE / EF GRAVY – MW comparisons (Fig. S5A/S5B) also demonstrated no significant 
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outliers, with the exception of TTN identification for AF: a likely false positive identification. 
Furthermore, the amino acid proportions in the identified protein sequences did not show any 
noteworthy trends related to residue charge or hydrophobicity (see Supporting Information). 
An overall nonspecific loss of serum proteins from a Blue-Native gel upon IAPP amyloid-
corona formation was additionally observed in an electrophoresis-based pilot study (Fig. S6).  
Protein networks for amyloid-corona complexes. The second qualitative analysis undertaken 
used the STRING resource (string-db.org)48,49 to identify molecular actions and enriched 
functional associations across the corona protein network. Multiple network annotations were 
enriched for the unique AF amyloid corona proteins (CC method, see Fig. S7). GO biological 
process Ubiquitin-dependent catabolic process (red) was enriched in the core network, in 
addition to the GO molecular function Carbohydrate derivative binding (blue) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways for ECM-receptor interaction 
(green), focal adhesion (yellow), proteasome (pink), PI3K/Akt (dark green) and the 
INTERPRO protein domain Concanavalin A-like lectin/glucanase domain (light blue). The 
proteins bound uniquely to amyloid fibrils may therefore interact with key elements of the 
cellular machinery including the proteasomal system, membrane adhesion factors and signal 
transduction pathways. These observations support the hypothesis that, similar to synthetic 
nanomaterial coronae, the amyloid-corona plays a role in changing biological identity to 
impact cellular interactions.45,50 By extension, if this interaction causes dysregulation, then 
this may provide a mechanistic foundation for pathology. As suggested earlier, this might 
include conformational changes to key proteins in these annotated pathways, the artificial 
concentration of proteins at amyloid plaque locations, or the ‘activation’ of plaques to act as 
scaffolds that support damaging molecular functions. The specific protein components 
driving such mechanisms are a key stage-gate going forward for this line of research. 
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These observations were mirrored for the unique STRING protein network generated from 
the unique QCM protein list (experiment AE), albeit with many more functional enrichments 
(Figure S8A/S8B). Figure 4 shows the enrichment of GO annotations for biological process 
Metabolic process (red) as well as molecular functions that include Small molecule binding 
(green) and Carbohydrate derivative binding (blue). The KEGG pathways, Focal adhesion 
(yellow), PI3K/Akt signaling pathway (orange), ECM-receptor interaction (pink), 
Phagosome (light blue) and PFAM protein domain Cadherin domain (dark green) were also 
enriched.  The core network of AE interactors thus contained proteins that may influence 
cellular metabolic networks. The AE network also mirrored elements enriched in the AF 
amyloid coronae, including Focal adhesion and PI3K/Akt signaling (Figure S7, Figure S8B). 
In addition to the functions annotated in Figure 4, it was not surprising to find elements of the 
coagulation cascade (see Figure S8C). Finally, in a departure from the AF network in Figure 
S7, catalytic and hydrolase activity were both annotated for the AE network (Figure S8B/S8C, 
suggesting a possible role for amyloid fibrils in the concentration, promotion or depletion of 
enzymatic activity through co-localization and potential protein conformational changes in 
the amyloid-corona.46  
The occurrence of overlapping GO/KEGG annotations across the unique AF and AE protein 
networks, in tandem with those annotations present in AE but missing in AF, gives additional 
credence to the hypothesis that the unique AF binders may in fact be hard corona proteins. 
The additional AE proteins may thus be part of either an extended hard corona network 
preserved by the less rigorous isolation conditions of the QCM method, or the postulated 
“soft” corona.  
The sum of these data provide evidence to suggest that the amyloid corona, and potentially its 
soft component, interacts not only with the coagulation cascades – as synthetic nanomaterials 
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are known to51,52 – but the coronae may cause amyloid to interfere in metabolic processes as 
well as adhesion and signal transduction pathways. It was promising to observe the latter 
results across two very different analytical approaches, including some shared proteins 
contributing to these network annotations: one example was 14-3-3 protein beta/alpha for the 
PI3K annotation (YWHAB). These observations cement the need to quantitatively evaluate the 
composition of these coronae in future. 
Structural analysis reveals key characteristics of the proteins enriched on amyloid. For the 
top ten serum proteins (by unique peptide count) in amyloid coronae identified by either CC 
(AF) or QCM (AE) methods, structural information available in the order of whole sequences, 
the sequence homologs, or sub-sequences was obtained by searching the protein databank 
(PDB) (Tables S1&S2). Corresponding three-dimensional (3D) structures of the AF and AE 
proteins were shown in Figs. S9&S10, respectively. For comparison, available structures of 
top FBS proteins (Table S3) were also shown in Fig. S11. Structural examination of the AF 
proteins (Fig. S9) suggests two salient features, having either fibrillar morphology (e.g., Figs. 
S9A,E,F) or multi-domains (e.g., Figs. S9B,C,D,F) with conformational flexibilities (e.g., the 
“open” and “close” conformations of neuropilin in Figs. S9C&D), in contrast to mostly 
globular structures of top FBS proteins (Fig. S11). A protein with either of the observed 
structural properties, such as the linear alpha-actinin-4 with coiled coils (Fig. 5A) or the 
multi-domain neuropilin with inter-domain plasticity (Fig. 5C), was able to make a large 
number of contacts with the fibrillar amyloid (Fig. 5), rendering a strong binding corona. On 
the other hand, available structures of the AE proteins (Fig. S10) included not only the strong 
amyloid-binding features observed in the AF proteins (Fig. S10B) but also globular proteins 
(e.g., the highly abundant serum albumin in Fig. S10A), the latter of which made less 
contacts and thus comparably weaker binding with amyloid fibrils (Figs. 5D,F) but still 
demonstrated a dynamic shift in secondary structure when its capacity for binding to IAPP 
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fibrils was individually assessed (Fig. S12). The observed differential amyloid-binding 
features of proteins by different experimental methodologies are consistent with their 
corresponding approaches to prepare the amyloid coronae - i.e., the relatively turbulent 
condition under CC left the ‘hard’ corona intact, while the less rigorous isolation conditions 
of QCM resulted in both ‘soft’ and ‘hard’ coronae. Additionally, it is notable that almost all 
of the top AF and AE proteins were negatively charged (Tables S1&S2), while the net 
charges of IAPP fibrils are positive. Hence, as proposed in our previous study with model 
proteins,32 electrostatic attractions likely play an important role in concordance with 
structural morphology and conformational plasticity in the formation of amyloid coronae.  
 
Conclusion  
Until recently, the idea that endogenous nanomaterials form their own protein corona in vivo, 
independent of specific biological interactions that would define their inherent functionality, 
has been largely overlooked. This is particularly important for amyloids, as they are 
ubiquitous components of not only human biology but even single-celled bacteria.53 
Collectively, the data of this study described the rapid generation of a largely heterogeneous 
coating of protein on the surface of pathogenic IAPP amyloid fibrils and plaques within a 
model environment, and demonstrated a multivariate array of amyloid-associative proteins 
pertaining to metabolic and cellular pathway functions. In addition, we have also introduced 
two optimized methodologies for streamlined isolation and identification of the amyloid-
protein corona that produced different compositions, albeit with concordant aspects that lend 
weight not only to the results reported, but to the importance of considering multiple 
approaches for every research question addressed. 
The association of a single protein with a given material has the potential to significantly 
impact its biological properties in vivo. For example, the human immunodeficiency virus 
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(HIV) envelope protein Tat, secreted by virus-infected cells, has been shown to associate 
with mature Aβ amyloid fibrils and induce increased neurotoxicity comparative to either the 
amyloid or protein alone,54 demonstrating a secondary source to amyloid-associated 
pathologies. Native protein-amyloid interactions can be analogously deleterious: clusterin, for 
example, a protein with increased expression in Alzheimer’s disease, has been shown to co-
localize with Aβ plaques in vivo, impacting both their localization and pathology.55  
An amyloid-protein corona may have the capacity to become biologically dynamic; the β-
sheet rich surface of amyloid structures has recently been shown to bind zinc ions and act as a 
potential catalyst for biochemical modification of interacting ligands, e.g. as an esterase.56,57 
If modulation of known binding sites, and exposure of cryptic sequences, were to occur 
through the unfolding of protein bound to the amyloid surface, this may impact the targeting 
capacity of anti-amyloid agents, and further introduce immunoreactivity if surface-exposed 
moieties are recognized as foreign. Furthermore, an amyloid-protein corona may undergo 
protein exchange during translocation, which could potentially modulate amyloid-associated 
biological interactions through the association of protective or cytotoxic proteins enriched in 
different milieu. For example, highly biocompatible synthetic nanomaterials, e.g. graphene, 
have been found capable of cytotoxic activity under certain conditions,58,59 of which their 
capacity to add cytotoxic proteins, such as amyloid species,60 to a preformed corona upon 
exposure to a new environment may play a contributory role. The innate structural 
polymorphism of amyloid species36,61 could also contribute to the diversity of the formed 
amyloid-protein corona, and how it may then affect biological processes in the surrounding 
milieu.  
The recent failure of Eli Lilly’s anti-amyloid antibody for treatment of AD during Phase III 
clinical trials62 underscores the need to pursue fundamental questions regarding amyloid-cell 
interactions, including the role of the protein corona on amyloid species in vivo. As such, the 
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methodologies we have introduced can be expanded, in conjunction with single-molecule 
techniques such as liquid-phase atomic force microscopy,63,64 to assess corona formation 
(kinetics, topology and enriched proteome) of other pathological amyloid in human plasma 
and sera from different environments – and, furthermore, the mechanisms by which coronal 
proteins and other factors potentially found associated with amyloids (e.g. metal ions) 
specifically impact key pathways at the cellular interface – thus advancing our understanding 
of amyloid pathologies in major diseases and supporting the development of anti-amyloid 
strategies that have so far eluded success. 
 
Methods 
Materials 
Lyophilized human islet amyloid polypeptide (IAPP) monomers (37-residue: 
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, disulfide bridge: 2–7; MW: 
3,906; sourced from either AnaSpec or Abcam) were allowed to fibrillate in Milli-Q water 
(pH 6.5) for > 1 week at room temperature to allow complete conversion of monomers and 
lower order amyloid pathway species to mature amyloid fibrils. Stock concentrations of IAPP 
amyloids were either 200 µM (~ 0.8 mg/mL) or 256 µM (~ 1 mg/mL). Fetal bovine serum 
(FBS; charcoal stripped), sourced from Sigma Aldrich, was passed through a 0.45 µm filter 
(PFTE membrane) to remove large aggregates and stored as 1 mL aliquots at -20 oC. 
Concentrations of both IAPP amyloid and FBS stocks utilized during individual experiments 
were established utilizing a NanoPhotometer (NanoDrop) with built-in Implemen software, 
and then diluted accordingly to their respective experimental concentrations in 1× phosphate 
buffered saline (PBS; pH 7). DL-1,4-Dithiothreitol (DTT) was purchased from Acros 
Organics. Trifluoroacetic acid (TFA) was acquired through Alfa Aesar. Iodoacetamide (IAA), 
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porcine trypsin and Dulbecco’s Modified Eagle’s Media (DMEM) were purchased from 
Sigma Aldrich. Human plasma was kindly donated by Joshua Glass. 
Transmission electron microscopy 
Carbon-coated formvar copper grids (400 mesh) were glow-discharged to promote 
hydrophilicity. Mature IAPP amyloids (final concentration: 0.1 mg/mL) were mixed with 
FBS at a 1:5 ratio by protein mass, and 10 µL aliquots were taken at 0 min (immediately), 5 
min, 30 min, 2 h and 24 h, and allowed to absorb to the grid for 60 s before excess liquid was 
drawn off using filter paper. Grids washed in 10 µL Milli-Q water and liquid drawn off as 
previously. Samples were then double-stained with 1% aqueous uranyl acetate by touching 
the grids to one 5 µL droplet and then drawing liquid off immediately, before placing the grid 
on a second droplet for 15 s in the dark and subsequently removing excess stain. TEM images 
were taken on a Tecnai F20 transmission electron microscope (FEI) utilizing an UltraScan 
1000 (2k × 2k) CCD camera (Gatan). IAPP amyloid fibril diameters were subsequently 
analyzed using Gatan Microscopy Suite software, with 100 points taken for each sample set 
assessed. Gaussian modeling of fibril diameter distribution (least squares fit) was applied 
using Prism (GraphPad). 
Helium ion microscopy 
Sample preparation: a suspension of 20,000 βTC6 cells in 150 µL DMEM (supplemented 
with 15% FBS) was incubated for 30 min at 37 oC with either water, IAPP amyloids (final 
applied concentration: 40 µM; ~ 0.16 mg/mL), 0.45 µm-filtered FBS (final applied 
concentration: 0.8 mg/mL) or IAPP amyloids pre-incubated with FBS (1:5 ratio by mass) for 
2 h at room temperature. PFA was then added to a final concentration of 2.5% and cells fixed 
at 4 oC overnight. Cells were then pelleted at 1.0 g for 3 min, supernatant removed, pellet 
resuspended through gentle pipetting in 20% ethanol, and incubated for 1 h at room 
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temperature. This sequence was then repeated, increasing ethanol concentration stepwise by 
20% until 80% was reached, with one further step at 90% ethanol then performed. Samples 
were then applied to carbon tape atop a specimen stub, and allowed to dry completely before 
imaging. HIM imaging was undertaken on a Zeiss Orion NanoFab instrument. 
Quartz crystal microbalance 
QSense QSX 301 Gold quartz crystal sensors (Biolin) were incubated with either 0.1 mg/mL 
mature IAPP amyloids in PBS buffer (n = 4) or PBS buffer alone controls (n = 4) for 17 h at 
room temperature. Excess liquid was then removed and sensors placed into a temperature-
controlled measurement chamber (Q-Sense Standard Flow module; 40 µL crystal surface 
interface volume) set at 25 oC. Experiments were run on a QSense E4 microbalance, utilizing 
QSoft 401 software to monitor the frequency shifts and resonance harmonics (recorded 
simultaneously at seven harmonics, two data points per second). Flow was controlled by an 
ISMATEC IPC high precision multichannel dispenser pump.  
The conditions applied to sensors were as follows: sensors were flushed with 1× PBS buffer 
for 10 min at 300 µL/min prior to the start of the experiment to remove any unbound amyloid, 
before lowering flow rate to 100 µL/min for one hour to establish a stable baseline. 
Subsequently, sensors functionalized with IAPP amyloids were further passivated with IAPP 
amyloid solution (0.1 mg/mL) for 10 min at 100 µL/min and a further hour at 10 µL/min, in 
order to ensure amyloid coverage of the entire sensor surface. Controls were run with PBS 
during this time. Flow rate was returned to 100 µL/min for 5 min to equilibrate the flow 
chamber. Sensors were then washed with PBS at 100 µL/min for 30 min. FBS (0.5 mg/mL, in 
PBS) was passivated across both sample sets at 100 µL/min for 55 min, and then sets were 
again flushed with PBS for 50 min. Sensors were then removed from the flow chambers for 
on-chip tryptic digestion of amyloid- or sensor-bound protein. 
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For the presentation of frequency shift and dissipation shift data, the third harmonic was 
utilized from each sample set and one data point per minute displayed on the plot. For data 
presentation, experiments were normalized to zero as the starting value for each plot to 
provide a common baseline. Error is represented as standard error of mean (SEM; n = 4).  
Protein corona isolation through centrifugal capture 
VivaSpin 2 1,000 kDa spin columns were equilibrated with 1× PBS and centrifuged for 10 
min at 6461 g on a SciQuip 2-16 centrifuge (Sigma). A 400 µL aliquot of IAPP amyloid (0.5 
mg/mL), FBS (2.5 mg/mL; pre-filtered through 0.45 µm filter) or IAPP amyloids pre-
incubated with FBS at a mass ratio of 1:5 for 2 h at room temperature was added to the spin 
column, mixed well, and then samples were centrifuged at 6461 g for 10 min. The filtrate was 
recovered from the bottom section of the apparatus, and the volume in the upper section was 
made up to 400 µL with 1× PBS, mixed well, and then centrifuged as previously. This 
process was repeated three additional times. The lower section of the spin column was then 
washed out with HPLC water to remove any remaining free protein prior to on-filter tryptic 
digestion of captured amyloid-bound protein. 
‘Soft’ tryptic digestion of amyloid protein corona 
To separate and digest corona proteins from captured amyloid, tryptic digestion was 
performed under mild conditions, hereby referred to as a ‘soft’ digestion. For amyloid-protein 
corona samples collected by the centrifugal capture method, all steps were carried out at the 
spin column filter interface; concordantly, for the QCM method, reagents were added 
sequentially to a liquid meniscus atop the sensor chip. 
Captured amyloid on spin column filters and quartz crystal sensors was incubated with 0.1% 
RapiGest SF surfactant (Waters) in 50 mM NH4HCO3 at room temperature for 1 h. Disulfide 
reduction was carried out at room temperature for 1 h through addition of DTT (in 50 mM 
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NH4HCO3) to a final concentration of 10 mM. Proteins were subsequently alkylated using 
IAA (in 50 mM NH4HCO3) over 15 min in the dark at room temperature, with the mixture 
gently agitated every 5 min. Reduced and alkylated corona proteins were washed from quartz 
crystal sensors using RapiGest and collected in Eppendorf tubes prior to tryptic digestion. 
Porcine trypsin (in 50 mM NH4HCO3) was added to an approximate final concentration ratio 
of 1:100 (trypsin : corona proteins) and proteins were digested for 13-17 h at 37 oC.  Digested 
proteins from centrifugal capture samples were eluted from the spin column filter through 
centrifugation (5 min, 6461 g), and all digests were then quenched with TFA. Samples were 
then concentrated using a Savant SpeedVac Plus (model SC110AR) vacuum centrifuge and 
reconstituted in 2% acetonitrile (ACN), 0.1% TFA, for analysis using MS. 
Nano liquid crystal electrospray tandem mass spectroscopy (nLC-ESI-MS-MS) 
All samples were first desalted on C18 StageTips as described elsewhere,65 and 
approximately 10 µg of tryptic peptides solubilized in 50 µL 2% ACN/0.1% TFA were 
collected from all controls for proteomic analysis. Tryptic peptides were separated by 
reversed phase chromatography prior to mass spectrometry analysis, utilizing two columns: 
an Acclaim PepMap µ-precolumn cartridge 300 µm i.d. × 5 mm, 5 µm, 100 Å, and an 
Acclaim PepMap RSLC 75 µm × 50 cm, 2 µm, 100 Å (Thermo Scientific) installed on an 
Ultimate 3000 RSLCnano system (Dionex). Mobile phase buffer A was composed of 0.1% 
aqueous formic acid (FA) and mobile phase B was composed of 80% ACN containing 0.1% 
FA. Samples were loaded onto the µ-precolumn and equilibrated in 2% aqueous ACN 
containing 0.1% TFA for 8 min at 10 µL min-1, and peptides were subsequently eluted onto 
the analytical column at 250 nL min-1 by increasing the mobile phase B concentration from 8% 
B to 35% over 53 min then to 80% B over 2 min, followed by a 15 min re-equilibration at 4% 
B.  
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Eluting peptides were converted to gas-phase ions by means of electrospray ionization (ESI) 
and analyzed on a Thermo Orbitrap Fusion (Q-OT-qIT, Thermo Scientific). Survey scans of 
peptide precursors from 375 to 1500 m/z were performed at 120K resolution (at 200 m/z) with 
a 5 × 105 ion count target. Tandem MS was performed by isolation at 1.6 Th using the 
quadrupole, HCD fragmentation with normalized collision energy of 33, and rapid scan MS 
analysis in the ion trap. The MS-MS ion count target was set to 5 × 103 and the max injection 
time was 150 ms. Precursors with charge state 2–6 were selected and sampled for MS-MS. 
The dynamic exclusion duration was set to 35 s with a 10 ppm tolerance around the selected 
precursor and its isotopes. Monoisotopic precursor selection was turned on. The instrument 
was run in top speed mode with 2 s cycles. 
nLC-MS/MS queries, analysis and informatics 
Base peak and average ion chromatograms were created for each nLC-MS/MS analysis 
following conversion of *.RAW files to *.mzML (MSconvert, part of ProteoWizard v3.0.9248) 
using the R package xcms66 (see Supporting Information for script and chromatograms). 
*.RAW files for each experiment were searched together using the inbuilt Andromeda engine 
in MaxQuant (v1.6.0.16).41 Contaminants considered: Yes, Enzyme: Trypsin/P, Fixed 
modifications: Carbamidomethylation, Variable modifications: N-acetylation, Methionine 
oxidation. Additional MaxQuant parameters are reported in the Supporting Information. The 
Bos taurus reference proteome dated 21/12/2017 (UP000009136_9913.fasta) was used for 
searches – except the repeat queries for experiment A (amyloid only CC), which used a 
Homo sapiens reference proteome dated 21/12/2017 (UP000005640_9606.fasta).  
Reference proteome(s) source:  
ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/reference_proteomes/. 
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Summary.txt and proteinGroup.txt files from each MaxQuant search were combined using a 
custom R67 script, which is formatted as an Rmarkdown68 *.html report (available as 
Supporting Information, along with details of analysis and custom R scripts).  
Unique protein ID lists for experimental subsets AE and AF were matched to STRING 
identifiers using the uniprot ID mapping tool (http://www.uniprot.org/uploadlists/) and these 
identifiers were submitted to the online STRING resource for protein network analysis.48,49 
Experimental and database interactions were considered for a minimum interaction score of 
0.400, with no additional interactors (only submitted list), against a whole genome 
background. Gene ontology (GO), pathway and protein domain enrichments were annotated 
using the online interface and downloaded as high resolution annotated protein network 
images for inclusion in this manuscript. Molecular action and evidence (functional 
association) networks were considered as indicated. Figures (Venn, pI/GRAVY/MW, 
networks) were formatted, annotated and re-exported using InkScape (v0.91, inkscape.org). 
Structural analysis 
For a given serum protein, the 3D structure information was extracted from the protein 
databank (PDB) by searching in the order of the whole sequence, the close homologs (e.g., 
human), or the sub-sequences. PDB IDs for top AE, AF and FBS proteins were listed in 
Tables S1, S2 & S3, respectively. The net charge of a given protein in Tables S1-3 was 
estimated by counting the number of basic and acidic amino acids under physiological 
conditions, i.e. Arg and Lys residues were assigned +1, Asp and Glu were assigned -1, while 
His was neutral. The corresponding 3D structures of AE and AF proteins were shown in Figs. 
S9&S10.  
The IAPP fibril model was constructed with 80 IAPPs forming a two-layered fibril using the 
solid-state NMR-derived constraints,36 which was assigned a ~1.5 oC left-handed twist 
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between consecutive IAPP beta-sheets according the experimentally identified fibril 
morphologies.69 The binding structure between a protein and the amyloid fibril in Fig. 5 was 
approximated by aligning the two molecules with maximum contacts.  
Statistics 
Where applicable, a one-way analysis of variance (ANOVA) test with Tukey’s correction for 
multiple comparisons was performed; for amyloid fibril diameter comparisons, n = 100, 
degrees of freedom = 699 (treatment = 693, residual = 6), F = 36.05. Data were considered 
significant when p < 0.05.  
Data availability 
The datasets generated during and/or analyzed during the current study are available from the 
corresponding author on reasonable request. 
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Tables 
Table 1A. Top 12 unique amyloid serum coronae (AF) proteins from the CC method. 
# Uniprot ID Protein name Unique peptides 
1 A5D7D1 Alpha-actinin-4 22 
2 P41361 Antithrombin-III 15 
3 P00978 Protein AMBP 14 
4 E1BMX5 Neuropilin 13 
5 E1BEL6 Neuropilin 12 
6 F1MMT2 Laminin subunit alpha 2 8 
7 P13213 SPARC 7 
8 F1MSA6 Uncharacterized protein 7 
9 F1MC48 IQ motif containing GTPase activating protein 1 7 
10 F1MKG2 Collagen type VI alpha 2 chain 6 
11 F1MHP5 Fms related tyrosine kinase 4 6 
12 F1MD77 Laminin subunit gamma 1 6 
                        *Ranked by the number of unique peptides matched to sequences using an Andromeda database query. 
 
Table 1B. Top 12 unique amyloid serum coronae (AE) proteins from the QCM method. 
# Uniprot ID Protein name Unique peptides 
1 A0A140T897 Serum albumin 72 
2 F1N3A1 Thrombospondin-1 40 
3 E1BGJ0 LDL receptor related protein 1 36 
4 P07224 Vitamin K-dependent protein S 33 
5 F1MJK3 Uncharacterized protein 29 
6 F1MMP5 Inter-alpha-trypsin inhibitor heavy chain H1 28 
7 P01267 Thyroglobulin 27 
8 E1BKL9 Uncharacterized protein 24 
9 Q0P569 Nucleobindin-1 23 
10 P35445 Cartilage oligomeric matrix protein 23 
11 Q3SWX5 Cadherin-6 19 
12 G3MYZ3 Afamin 19 
                        *Ranked by the number of unique peptides matched to sequences using an Andromeda database query. 
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Figures 
 
Figure 1. Formation and characterization of IAPP amyloid-protein corona in FBS. A: TEM 
imaging (upper panel; scale: 100 nm) and associated analysis of fibril diameter (lower panel; 
n = 100 points sampled) of amyloid exposed to FBS over 24 h, with a comparative 
measurement after 24 h exposure to human plasma proteins. **** p < 0.0001. B: QCM 
characterization of amyloid corona formation on an IAPP amyloid functionalized surface 
(IAPP pre-coat) or gold (uncoated) under flow over 1 h (left panel) with comparison of the 
soft (pre-wash) and hard (post-wash) coronae (right panel). Error: SEM (n = 4). C: HIM 
imaging of βTC6 cells exposed for 30 min in vitro to either amyloid (I), amyloid + FBS, pre-
incubated for 2 h at RT (II), FBS alone (III), or no treatment applied (IV). Scale: 4 µm. 
Concentration of IAPP amyloid in all experiments: 0.1 mg/mL; FBS: 0.5 mg/mL. 
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Figure 2. Sample nomenclature, replicates, methods and analytical pipeline implemented for 
centrifugal capture (CC) and quartz crystal micro-balance (QCM) amyloid-corona 
characterization by nano-liquid chromatography MS/MS (nLC-MS/MS), including 
MaxQuant Andromeda searches, protein attribute comparisons and protein network analysis 
(STRING). Experimental nomenclature is provided, including amyloid control (A), fetal 
bovine serum (FBS) only control (F) and amyloid plus FBS (AF) for CC preparations, as well 
as FBS control (EF) and amyloid plus FBS (AE) for QCM preparations. 
Page 28 of 38
ACS Paragon Plus Environment
ACS Nano
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
29 
 
 
Figure 3. Overlap of protein identifications made using nLC-MS/MS analysis of centrifugal 
capture (CC, A) and quartz crystal microbalance (QCM, B) amyloid corona experiments. The 
GRAVY/pI relationships for unique CC (AF) and QCM (AE) amyloid serum coronae are 
shown in yellow in panels D-F. Blue markers in C-D are all identified AF experiment 
proteins and in E-F are unique serum only control (EF) proteins. All plots are overlaid onto 
the Bos taurus proteome background (gray). Labels are specific to designated regions of the 
plots (panels C/E: labels outside blue box, GRAVY ≤ -1.5 and ≥ 0.5, pI ≤ 4 and pI ≥ 10 | 
panel D: labels outside ranges GRAVY ≤ -1 and ≥ 0, pI ≤ 4.5 and ≥ 7, panel F: labels outside 
ranges GRAVY ≤ -1 and ≥ 0, pI ≤ 4.5 and ≥ 8.5). 
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Figure 4. Quartz crystal microbalance (QCM) method amyloid and serum corona (AE) 
STRING48,49 (string-db.org) protein network (molecular action) produced using database and 
experimental interactors, with a minimum interaction score of 0.400 and no additional 
interactors, against a whole Bos taurus genome background. Enrichment analysis and 
molecular action legends are included, in addition to predicted action effects – positive 
(arrowhead), negative (endpoint line), unspecified (endpoint circle). 
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Figure 5. Schematic binding between IAPP amyloid fibril and AF/AE proteins with 
maximal contact interface. The amyloid fibril is formed by β-sheets of composite peptides 
(grey). The binding of AF proteins – (A) alpha-actinin-4 (cyan), (B) protein AMBP (yellow) 
and (C) neuropilin in open (magenta) and closed (light pink) conformations – and AE 
proteins – (D) serum albumin (purple), (E) thrombospondin-1 (blue) and (F) cartilage 
oligomeric matrix protein (orange) – with the amyloid fibril was estimated by aligning them 
with maximum contact surface areas. Serum proteins are shown in cartoon format with 
dashed lines representing missing sequences without available structural information.  
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